A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Study summary

This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much PF-08046049/SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor cancers.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedPF-08046049

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Mesothelioma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 1, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?37 U.S. locations

Locations may change over time.

Who runs it?Seagen, a wholly owned subsidiary of Pfizer

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Interventions being studied: Drug: PF-08046049

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→Mesothelioma→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

All Parts: Participants must have disease that is relapsed, refractory, or intolerant to standard of care. Participants must have histologically or cytologically confirmed metastatic malignancy.
Participants must have one of the following tumor types:
Parts A and B: Participants must have metastatic or unresectable cutaneous melanoma.
Part C: Participants must have one of the following tumor types:
Cutaneous Melanoma
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Pancreatic Cancer
Mesothelioma
A pre-treatment biopsy or submission of archival tissue is required
For participants with cutaneous melanoma
Must have been previously treated with an anti-programmed death-1 (anti-PD-1) or anti-programmed death ligand-1 (anti-PD-L1) agent given alone or with other therapies.
Participants with a targetable BRAF mutation must have been treated with, been intolerant of, or been deemed ineligible to receive treatment with BRAF/MEK targeted therapy prior to study entry.
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
Measurable disease per RECIST v1.1 at baseline

Reasons someone may not be able to joinExclusion criteria

History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
Active central nervous system metastases or leptomeningeal disease. Participants with previously treated brain metastases may participate provided they are:
clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment,
they have no new or enlarging brain metastases,
and are off of corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study drug.
Prior therapies cannot include any drugs targeting CD228 or 4-1BB
Immunotherapy, biologics, and/or other approved or investigational antitumor treatment that is not completed 4 weeks prior to first dose of study drug, or within 2 weeks prior to the first dose of study drug if the underlying disease has progressed on treatment
Melanoma subtypes including acral, uveal, and mucosal are excluded

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

UCLA Hematology/Oncology - Administrative OfficeLos Angeles, California
The Angeles Clinic and Research Institue, A Cedars-Sinai AffiliateLos Angeles, California
Cedars-Sinai Medical CenterLos Angeles, California
Ronald Reagan UCLA Medical Center, Drug Information CenterLos Angeles, California
UCLA Hematology/OncologyLos Angeles, California
UCLA Hematology/ Oncology- PasadenaPasadena, California
UCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, California
UCSF Medical Center, Investigational PharmacySan Francisco, California
UCLA Hematology/Oncology - Santa BarbaraSanta Barbara, California
The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate (Emergency Back-up only)Santa Monica, California
UCLA Hematology - Oncology Clinic - Westlake VillageWestlake Village, California
Quest Diagnostics Incorporated - DenverDenver, Colorado

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 1, 2026. Always confirm current availability with the study team.

View original record ↗